Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines developer for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, will be involved in both events:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY: Cumbo will participate in a fireside chat on September 10, 2024, at 9:30 am ET.
2. Baird 2024 Global Healthcare Conference in New York, NY: Cumbo will present on September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the company's website, with a replay archived for 30 days. Institutional investors can arrange meetings with management through their H.C. Wainwright or Baird representatives.
Solid Biosciences (Nasdaq: SLDB), un sviluppatore di medicine genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Bo Cumbo, Presidente e CEO, parteciperà a entrambi gli eventi:
1. 26ª Conferenza Annuale di Investimenti Mondiali H.C. Wainwright a New York, NY: Cumbo parteciperà a un colloquio informale il 10 settembre 2024, alle 9:30 ora ET.
2. Conferenza Globale sulla Salute Baird 2024 a New York, NY: Cumbo presenterà il 11 settembre 2024, alle 12:50 ora ET.
Un webcast live del colloquio informale H.C. Wainwright sarà disponibile sul sito web dell'azienda, con una registrazione archiviata per 30 giorni. Gli investitori istituzionali possono organizzare incontri con il management attraverso i loro rappresentanti H.C. Wainwright o Baird.
Solid Biosciences (Nasdaq: SLDB), un desarrollador de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su participación en dos próximas conferencias para inversores. Bo Cumbo, Presidente y CEO, estará involucrado en ambos eventos:
1. 26ª Conferencia Anual Global de Inversión H.C. Wainwright en Nueva York, NY: Cumbo participará en una charla informal el 10 de septiembre de 2024, a las 9:30 am ET.
2. Conferencia Global de Salud Baird 2024 en Nueva York, NY: Cumbo presentará el 11 de septiembre de 2024, a las 12:50 pm ET.
Una transmisión en vivo de la charla de H.C. Wainwright estará disponible en el sitio web de la empresa, con una repetición archivada por 30 días. Los inversores institucionales pueden organizar reuniones con la dirección a través de sus representantes de H.C. Wainwright o Baird.
솔리드 바이오사이언스 (Nasdaq: SLDB)는 근육 및 심장 질환을 위한 정밀 유전자 의약품 개발업체로서 두 개의 예정된 투자자 컨퍼런스에 참여한다고 발표했습니다. 보 컴보, 사장 겸 CEO는 두 행사 모두에 참여할 예정입니다:
1. H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스 뉴욕, NY: 컴보는 2024년 9월 10일 오전 9시 30분 ET에 일대일 대화에 참여합니다.
2. 베어드 2024 글로벌 헬스케어 컨퍼런스 뉴욕, NY: 컴보는 2024년 9월 11일 오후 12시 50분 ET에 발표할 예정입니다.
H.C. 웨인라이트 대화의 생중계는 회사 웹사이트에서 제공되며, 30일 동안 다시 볼 수 있도록 기록됩니다. 기관 투자자들은 H.C. 웨인라이트 또는 베어드 대표를 통해 경영진과의 회의를 주선할 수 있습니다.
Solid Biosciences (Nasdaq: SLDB), un développeur de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa participation à deux conférences pour investisseurs à venir. Bo Cumbo, Président et CEO, sera présent à ces deux événements :
1. 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright à New York, NY : Cumbo participera à une discussion informelle le 10 septembre 2024, à 9h30 ET.
2. Conférence Mondiale sur la Santé Baird 2024 à New York, NY : Cumbo présentera le 11 septembre 2024, à 12h50 ET.
Une diffusion en direct de la discussion informelle H.C. Wainwright sera disponible sur le site Web de l'entreprise, avec une rediffusion archivée pendant 30 jours. Les investisseurs institutionnels peuvent organiser des réunions avec la direction par l'intermédiaire de leurs représentants H.C. Wainwright ou Baird.
Solid Biosciences (Nasdaq: SLDB), ein Entwickler von präzisen Gentherapien für neuromuskuläre und Herzkrankheiten, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Bo Cumbo, Präsident und CEO, wird bei beiden Veranstaltungen dabei sein:
1. 26. Jährliche Globale Investitionskonferenz von H.C. Wainwright in New York, NY: Cumbo wird am 10. September 2024 um 9:30 Uhr ET an einem informellen Gespräch teilnehmen.
2. Baird 2024 Globale Gesundheitskonferenz in New York, NY: Cumbo wird am 11. September 2024 um 12:50 Uhr ET präsentieren.
Ein Live-Webcast des informellen Gesprächs von H.C. Wainwright wird auf der Website des Unternehmens verfügbar sein, mit einer aufgezeichneten Wiederholung für 30 Tage. Institutionelle Investoren können Meetings mit dem Management über ihre Vertreter von H.C. Wainwright oder Baird vereinbaren.
- None.
- None.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- H.C. Wainwright 26th Annual Global investment Conference – New York, NY
Bo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 10, 2024, at 9:30 am ET.
- Baird 2024 Global Healthcare Conference – New York, NY
Mr. Cumbo will present on Wednesday, September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conferences may reach out to their H.C. Wainwright or Baird representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
What investor conferences will Solid Biosciences (SLDB) attend in September 2024?
When and where will Bo Cumbo, CEO of Solid Biosciences (SLDB), present at the Baird 2024 Global Healthcare Conference?
How can investors access the webcast of Solid Biosciences' (SLDB) fireside chat at the H.C. Wainwright conference?
What type of medicines does Solid Biosciences (SLDB) develop?
